Which has higher valuation and earnings, SEPN or UPB?

Septerna has higher revenue and earnings than Upstream Bio. Septerna is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Septerna $45.95M 33.89 -$48.88M -$0.81 N/A Upstream Bio $2.85M 136.34 -$143.44M -$2.91 N/A

Is SEPN or UPB more profitable?

Septerna has a net margin of -49.88% compared to Upstream Bio's net margin of -4,718.96%. Septerna's return on equity of -12.72% beat Upstream Bio's return on equity. Company Net Margins Return on Equity Return on Assets Septerna -49.88% -12.72% -8.87% Upstream Bio -4,718.96% -43.82% -42.27%

Upstream Bio (UPB) Competitors

$7.14 -0.14 (-1.92%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$7.16 +0.02 (+0.28%)

As of 07/14/2026 05:48 PM Eastern

Compare

UPB vs. AVBP, MRVI, SEPN, MPLT, and COAG

Should you buy Upstream Bio stock or one of its competitors? MarketBeat compares Upstream Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Upstream Bio include ArriVent BioPharma (AVBP), Maravai LifeSciences (MRVI), Septerna (SEPN), Maplight Therapeutics (MPLT), and Hemab Therapeutics (COAG). These companies are all part of the "pharmaceutical products" industry.

How does Upstream Bio compare to ArriVent BioPharma?

Upstream Bio (NASDAQ:UPB) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

ArriVent BioPharma has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat ArriVent BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
ArriVent BioPharma	N/A	-48.98%	-45.44%

Upstream Bio has higher revenue and earnings than ArriVent BioPharma. ArriVent BioPharma is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	136.34	-$143.44M	-$2.91	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

9.5% of ArriVent BioPharma shares are owned by institutional investors. 16.5% of Upstream Bio shares are owned by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Upstream Bio presently has a consensus price target of $33.17, suggesting a potential upside of 364.52%. ArriVent BioPharma has a consensus price target of $44.83, suggesting a potential upside of 37.78%. Given Upstream Bio's higher possible upside, equities research analysts clearly believe Upstream Bio is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, ArriVent BioPharma had 2 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for ArriVent BioPharma and 1 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.44 beat ArriVent BioPharma's score of 0.47 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Upstream Bio	Positive
ArriVent BioPharma	Neutral

Upstream Bio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Summary

Upstream Bio beats ArriVent BioPharma on 9 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Maravai LifeSciences?

Upstream Bio (NASDAQ:UPB) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Maravai LifeSciences has a net margin of -51.07% compared to Upstream Bio's net margin of -4,718.96%. Maravai LifeSciences' return on equity of -17.87% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Maravai LifeSciences	-51.07%	-17.87%	-9.08%

Maravai LifeSciences has higher revenue and earnings than Upstream Bio. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	136.34	-$143.44M	-$2.91	N/A
Maravai LifeSciences	$185.74M	9.05	-$130.77M	-$0.71	N/A

50.3% of Maravai LifeSciences shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 2.5% of Maravai LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Upstream Bio. MarketBeat recorded 3 mentions for Maravai LifeSciences and 1 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.44 beat Maravai LifeSciences' score of 1.22 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Upstream Bio	Positive
Maravai LifeSciences	Positive

Upstream Bio presently has a consensus target price of $33.17, suggesting a potential upside of 364.52%. Maravai LifeSciences has a consensus target price of $5.50, suggesting a potential downside of 15.51%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Upstream Bio is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Upstream Bio has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, Maravai LifeSciences has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market.

Summary

Upstream Bio and Maravai LifeSciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Upstream Bio compare to Septerna?

Septerna (NASDAQ:SEPN) and Upstream Bio (NASDAQ:UPB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

Septerna has a net margin of -49.88% compared to Upstream Bio's net margin of -4,718.96%. Septerna's return on equity of -12.72% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Septerna has higher revenue and earnings than Upstream Bio. Septerna is trading at a lower price-to-earnings ratio than Upstream Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	33.89	-$48.88M	-$0.81	N/A
Upstream Bio	$2.85M	136.34	-$143.44M	-$2.91	N/A

Septerna currently has a consensus price target of $45.89, suggesting a potential upside of 32.86%. Upstream Bio has a consensus price target of $33.17, suggesting a potential upside of 364.52%. Given Upstream Bio's higher probable upside, analysts clearly believe Upstream Bio is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Septerna had 1 more articles in the media than Upstream Bio. MarketBeat recorded 2 mentions for Septerna and 1 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.44 beat Septerna's score of 0.94 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Septerna	Positive
Upstream Bio	Positive

Septerna has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Upstream Bio has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Summary

Septerna beats Upstream Bio on 11 of the 15 factors compared between the two stocks.

How does Upstream Bio compare to Maplight Therapeutics?

Upstream Bio (NASDAQ:UPB) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Upstream Bio currently has a consensus price target of $33.17, suggesting a potential upside of 364.52%. Maplight Therapeutics has a consensus price target of $39.10, suggesting a potential upside of 3.14%. Given Upstream Bio's higher possible upside, analysts plainly believe Upstream Bio is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	5 Strong Buy rating(s)	3.13

Upstream Bio has higher revenue and earnings than Maplight Therapeutics. Upstream Bio is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	136.34	-$143.44M	-$2.91	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Maplight Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Maplight Therapeutics' return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Maplight Therapeutics had 4 more articles in the media than Upstream Bio. MarketBeat recorded 5 mentions for Maplight Therapeutics and 1 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.44 beat Maplight Therapeutics' score of 0.70 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Upstream Bio	Positive
Maplight Therapeutics	Positive

Summary

Maplight Therapeutics beats Upstream Bio on 8 of the 13 factors compared between the two stocks.

How does Upstream Bio compare to Hemab Therapeutics?

Hemab Therapeutics (NASDAQ:COAG) and Upstream Bio (NASDAQ:UPB) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Hemab Therapeutics has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Hemab Therapeutics' return on equity of 0.00% beat Upstream Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hemab Therapeutics	N/A	N/A	N/A
Upstream Bio	-4,718.96%	-43.82%	-42.27%

Hemab Therapeutics currently has a consensus target price of $48.00, indicating a potential upside of 10.83%. Upstream Bio has a consensus target price of $33.17, indicating a potential upside of 364.52%. Given Upstream Bio's higher probable upside, analysts plainly believe Upstream Bio is more favorable than Hemab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hemab Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Hemab Therapeutics had 10 more articles in the media than Upstream Bio. MarketBeat recorded 11 mentions for Hemab Therapeutics and 1 mentions for Upstream Bio. Upstream Bio's average media sentiment score of 1.44 beat Hemab Therapeutics' score of 0.82 indicating that Upstream Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Hemab Therapeutics	Positive
Upstream Bio	Positive

Hemab Therapeutics has higher earnings, but lower revenue than Upstream Bio. Upstream Bio is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hemab Therapeutics	N/A	N/A	N/A	-$23.98	N/A
Upstream Bio	$2.85M	136.34	-$143.44M	-$2.91	N/A

Summary

Hemab Therapeutics beats Upstream Bio on 7 of the 11 factors compared between the two stocks.

Get Upstream Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPB vs. The Competition

Export

Metric	Upstream Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$396.18M	$3.68B	$6.85B	$12.44B
Dividend Yield	N/A	2.19%	2.68%	8.42%
P/E Ratio	-2.45	20.98	27.01	24.38
Price / Sales	136.34	311.11	522.34	92.57
Price / Cash	N/A	143.66	48.59	59.36
Price / Book	1.14	8.54	10.80	6.33
Net Income	-$143.44M	$23.83M	$3.59B	$331.02M
7 Day Performance	-10.53%	-2.77%	-1.49%	-0.33%
1 Month Performance	17.05%	5.85%	2.79%	-1.29%
1 Year Performance	-35.91%	52.15%	28.56%	21.30%

Upstream Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPB Upstream Bio	2.272 of 5 stars	$7.14 -1.9%	$33.17 +364.5%	-39.1%	$396.18M	$2.85M	N/A	38	News Coverage Positive News
AVBP ArriVent BioPharma	2.6682 of 5 stars	$34.18 -0.9%	$43.14 +26.2%	+48.8%	$1.61B	N/A	N/A	40
MRVI Maravai LifeSciences	1.7979 of 5 stars	$5.92 +0.3%	$5.50 -7.1%	+143.8%	$1.52B	$185.74M	N/A	610	News Coverage Positive News
SEPN Septerna	2.2543 of 5 stars	$35.83 +7.1%	$45.89 +28.1%	+187.6%	$1.51B	$45.95M	N/A	N/A
MPLT Maplight Therapeutics	1.5158 of 5 stars	$37.06 +5.8%	$38.80 +4.7%	N/A	$1.49B	N/A	N/A	109

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPB) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Upstream Bio (UPB) Competitors

UPB vs. AVBP, MRVI, SEPN, MPLT, and COAG

How does Upstream Bio compare to ArriVent BioPharma?

Summary

How does Upstream Bio compare to Maravai LifeSciences?

Summary

How does Upstream Bio compare to Septerna?

Summary

How does Upstream Bio compare to Maplight Therapeutics?

Summary

How does Upstream Bio compare to Hemab Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Upstream Bio (UPB) Competitors

UPB vs. AVBP, MRVI, SEPN, MPLT, and COAG

How does Upstream Bio compare to ArriVent BioPharma?

Is UPB or AVBP more profitable?

Which has better valuation & earnings, UPB or AVBP?

Do insiders and institutionals hold more shares of UPB or AVBP?

Do analysts recommend UPB or AVBP?

Does the media favor UPB or AVBP?

Which has more volatility and risk, UPB or AVBP?

Summary

How does Upstream Bio compare to Maravai LifeSciences?

Is UPB or MRVI more profitable?

Which has higher earnings and valuation, UPB or MRVI?

Do insiders and institutionals believe in UPB or MRVI?

Does the media prefer UPB or MRVI?

Do analysts recommend UPB or MRVI?

Which has more volatility and risk, UPB or MRVI?

Summary

How does Upstream Bio compare to Septerna?

Is SEPN or UPB more profitable?

Which has higher valuation and earnings, SEPN or UPB?

Do analysts prefer SEPN or UPB?

Does the media favor SEPN or UPB?

Which has more volatility and risk, SEPN or UPB?

Summary

How does Upstream Bio compare to Maplight Therapeutics?

Do analysts rate UPB or MPLT?

Which has stronger valuation and earnings, UPB or MPLT?

Is UPB or MPLT more profitable?

Does the media favor UPB or MPLT?

Summary

How does Upstream Bio compare to Hemab Therapeutics?

Is COAG or UPB more profitable?

Do analysts prefer COAG or UPB?

Does the media favor COAG or UPB?

Which has higher earnings and valuation, COAG or UPB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB vs. The Competition

Upstream Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools